790 CLINICAL IMPLICATIONS OF P53 GENE MUTATION IN BLADDER CANCER

Abstract

You have accessJournal of UrologyBladder Cancer: Basic Research I1 Apr 2010790 CLINICAL IMPLICATIONS OF P53 GENE MUTATION IN BLADDER CANCER Uttam Mete, Saurabh Pandya, Anuradha Chakraborti, Nandita Kakkar, and Arup Mandal Uttam MeteUttam Mete More articles by this author , Saurabh PandyaSaurabh Pandya More articles by this author , Anuradha ChakrabortiAnuradha Chakraborti More articles by this author , Nandita KakkarNandita Kakkar More articles by this author , and Arup MandalArup Mandal More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.1439AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Aims of our study were to assess frequency of P53 gene mutations in patients with transitional cell carcinoma of urinary bladder and to find out its correlation with standard clinical and histological parameters for tumor recurrence and progression. METHODS Tumor tissue samples of 54 patients with transitional cell carcinoma(TCC) of urinary bladder obtained by TURBT or radical cystectomy were examined histopathologically. P53 mutations were assessed by DNA isolation and PCR-SSCP ( polymerase chain reaction- single strand conformation polymorphism) analysis. Data were analysed by Fisher's two tailed t-test, Pearson's chi-square test and non-parametric testes where necessary. Uni and multi variate analysis was performed with P53 mutations as dependent variable. RESULTS 27 patients had presented with primary tumors (18 superficial, 9 invasive), remaining 27 patients had recurrent disease. Out of 54 patients 15 (27.8%) had p53 mutations detected in exons 5,6 and 7. P53 mutations were more in invasive tumor as compared to superficial tumor {8/39 (20%) vs 7/15 (47%)}. Progression of disease was associated with higher frequency of p53 mutations {5/13 (38%) vs 1/14 (7%)}. There was significantly higher number of mutations with increasing size of tumor (P=0.001) higher grade (P=0.003) and stage of tumor (0.028). CONCLUSIONS P53 mutations are associated with disease progression and aggressive behavior. Therefore patients having tumor with P53 mutations should be followed up closely. This molecular prognosticator may play a role in the clinical routine management of patients with bladder tumor. Further studies should explore their potential clinical significance taking into their cost-effectiveness. Chandigarh, India© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e309 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Uttam Mete More articles by this author Saurabh Pandya More articles by this author Anuradha Chakraborti More articles by this author Nandita Kakkar More articles by this author Arup Mandal More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...